歡迎光臨源葉生物,登錄 | 注冊 |
當前位置: 首頁 > 小分子抑制劑 > DNADamage/DNARepair > Trovafloxacin

瀏覽歷史

S29883

Trovafloxacin

源葉(MedMol) 98%
  • 英文名:
  • TROVAFLOXACIN
  • 別名:
  • 曲伐沙星;曲氟沙星;(1Α,5Α,6Α)-7-(6-氨基-3-氮雜二環(huán)[3.1.0]己-3-基)-1-(2,4-二氟苯基)-6-氟-1,4-二氫-4-氧-1,8-萘啶-3-羧酸;特伐沙星;曲氟沙星;TROVAFLOXACIN;1,8-Naphthyridine-3-carboxylic acid, 7-(1.alpha.,5.alpha.,6.alpha.)-6-amin
  • CAS號:
  • 147059-72-1
  • 分子式:
  • C20H15F3N4O3
  • 分子量:
  • 416.35
  • 核磁/質譜:
品牌貨號產品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數量計量單位 加入購物車...
源葉(MedMol) S29883-10mg 98% ¥800.00元 1 - - - EA 加入購物車
源葉(MedMol) S29883-50mg 98% ¥2800.00元 1 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權與保護申明》,到貨后將短信提示。
提交

產品介紹

參考文獻(1篇)

質檢證書(COA)

摩爾濃度計算器

相關產品

  • 產品描述:

    Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1

  • 靶點: Quinolone;DNAgyrase;Topoisomerase;Antibacterial;Antibiotic
  • 體內研究:
    Trovafloxacin (150 mg/kg; oral administration; male C57BL/6 J mice) treatment disrupts TNF-induced p65 nuclear translocation. Trovafloxacin treatment increases expression of early NF-κB-related factors A20 and IκBα. Trovafloxacin, when administered in combination with lipopolysaccharide (LPS) or TNF to mice induces severe liver toxicity associated with vast apoptotic areas in the liver, increased serum levels of alanine amino transferases (ALT) and pro-inflammatory cytokines.
  • 參考文獻:
    1. Giustarini G, et al. The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. 2. Poon IK, et al. Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature. 2014 Mar 20;507(7492):329-34. 3. Gootz TD, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7.
  • 溶解性: DMSO  :  10  mg/mL  (24.02  mM;  ultrasonic  and  adjust  pH  to  4  with  HCl)
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.402 ml 12.009 ml 24.018 ml
    5 mM 0.48 ml 2.402 ml 4.804 ml
    10 mM 0.24 ml 1.201 ml 2.402 ml
    50 mM 0.048 ml 0.24 ml 0.48 ml
  • 注意:部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。
  • 產品描述:

    Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1

  • 靶點: Quinolone;DNAgyrase;Topoisomerase;Antibacterial;Antibiotic
  • 體內研究:
    Trovafloxacin (150 mg/kg; oral administration; male C57BL/6 J mice) treatment disrupts TNF-induced p65 nuclear translocation. Trovafloxacin treatment increases expression of early NF-κB-related factors A20 and IκBα. Trovafloxacin, when administered in combination with lipopolysaccharide (LPS) or TNF to mice induces severe liver toxicity associated with vast apoptotic areas in the liver, increased serum levels of alanine amino transferases (ALT) and pro-inflammatory cytokines.
  • 參考文獻:
    1. Giustarini G, et al. The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. 2. Poon IK, et al. Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature. 2014 Mar 20;507(7492):329-34. 3. Gootz TD, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7.
  • 溶解性: DMSO  :  10  mg/mL  (24.02  mM;  ultrasonic  and  adjust  pH  to  4  with  HCl)
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.402 ml 12.009 ml 24.018 ml
    5 mM 0.48 ml 2.402 ml 4.804 ml
    10 mM 0.24 ml 1.201 ml 2.402 ml
    50 mM 0.048 ml 0.24 ml 0.48 ml
  • 注意:部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。
輸入產品批號:

本計算器可幫助您計算出特定溶液中溶質的質量、溶液濃度和體積之間的關系,公式為:


質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產品僅用作科學研究,銷售產品行為均適用于我司網上所列通用銷售條款。
点击收缩